FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer By Ogkologos - July 8, 2026 91 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POTOMAC study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Indications for Datopotamab Deruxtecan High-Dose Chemotherapy Followed by ASCT Improves Survival Compared with Non-myeloablative Consolidation in Primary CNS Lymphoma Belzutifan Plus Lenvatinib Improves Outcomes Over Cabozantinib in Patients with Advanced RCC Following Progression to PD1 or PD-L1 Inhibitors MOST POPULAR ESMO Welcomes European Parliament (EP) Draft Report on Psychosocial Risks at... April 2, 2026 FDA Approves Bosutinib for Paediatric Patients with Chronic Myelogenous Leukaemia October 13, 2023 Trastuzumab Emtansine Improves OS with Sustained Improvement in iDFS Among Patients... January 22, 2025 Entrectinib Is Effective and Well Tolerated in Patients with Treatment-Naïve ROS1-positive... July 19, 2024 Load more HOT NEWS Take a Small Step Diverse Genomic and Histologic Mechanisms of Resistance to KRASG12C Inhibition Described Διαφημιστείτε Marking Breast Cancer Awareness Month 2025, ESMO Calls for Increasing Awareness...
